Welcome
Viral Genetics, Inc. is a biotechnology research and development company researching new treatments and methods of detection for HIV/AIDS, Lyme Disease, staph and strep, cancer and certain other autoimmune and infectious diseases. Two approaches based on patent rights licensed from the University of Colorado and University of Vermont form the basis of our research: “Targeted Peptides” and “Metabolic Disruption”. As we near completion of our preclinical research, we are preparing pre-IND applications for FDA clinical trials of compounds from these approaches in the US. We also have a subsidiary called VG Energy that is separately developing the non-disease applications of our metabolic technology.Click here for more information.
Recent News
Viral Genetics April 2012 Shareholder Update Alerts Investors to Product Pipeline Expansion and Developments at Algal BioFuels SubsidiaryViral Genetics (Pinksheets: VRAL.PK - News) today published its April 2012 Letter to Shareholders. Providing updates on the company’s progress, the letter discusses the expanded product development pipeline for the Targeted Peptide and the Metabolic Disruption Technology platforms, as well as developments at the VG Energy subsidiary, and moves being made to manage this new growth.
Click here for more information.
Metacytolytics
MetaCytoLytics is a subsidiary of Viral Genetics that is focused on the development of our Metabolic Disruption technology that has application in the treatment of various diseases including cancer through the manipulation of how certain types of cells use or store fats and sugars to generate internal energy.Through manipulation of tumor cells’ metabolisms, we are studying how to cause their death and are working to develop treatments for drug resistant tumors — the leading cause of death from cancer. Currently the company is working at development of a compound for the treatment of glioblastoma, a deadly form of brain cancer, and has planned an investigator’s IND for January 2011.
Click here for more information.